Clinical Trials Directory

Trials / Unknown

UnknownNCT03964129

BMAC Nerve Allograft Study

Clinical Evaluation of Decellularized Nerve Allograft With Autologous Bone Marrow Aspirate Concentrate (BMAC) to Improve Peripheral Nerve Repair and Functional Outcomes

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Brooke Army Medical Center · Federal
Sex
All
Age
18 Years – 74 Years
Healthy volunteers
Not accepted

Summary

This study is a prospective, multi-center, proof of principle, phase I human safety study evaluating the sequential treatments of the Avance Nerve Graft, a commercially available decellularized processed peripheral nerve allograft, with autologous Bone Marrow Aspirate Concentrate (BMAC), a source of stem cells, for the repair of peripheral nerve injuries up to 7 cm in length. The purpose of this study is to establish a knowledge product, evaluating the safety profile of the Avance Nerve Graft, followed by the application of BMAC to support further investment into the promising area of using stem cells in conjunction with scaffolds.

Conditions

Interventions

TypeNameDescription
PROCEDUREAvance Nerve Graft with Autologous BMACThe Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested. Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained. Of the 7 to 10 ml of final BMAC that is yielded, half (3.5 to 5 ml) of the final concentrate, will be injected on top of the Avance Nerve Graft following coaptation. The second half (3.5 to 5 ml) of the final concentrate will be inserted into a sterile tube containing culture media and shipped overnight to Cleveland Clinic Lerner Research Institute for cell processing and colony assay to confirm that the BMAC indeed contains autologous bone marrow stem cells.

Timeline

Start date
2017-08-22
Primary completion
2020-11-30
Completion
2021-06-01
First posted
2019-05-28
Last updated
2020-07-16

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT03964129. Inclusion in this directory is not an endorsement.